€2.65
2.93%
Xetra, Nov 20, 09:15 am CET. Market open.
ISIN
DE0005664809
Symbol
EVT
Index

Evotec Stock News

Neutral
●
PRNewsWire
●
one day ago
FDA clearance expands partnered molecular glue pipeline Achievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high unmet need HAMBURG, Germany, Nov. 19, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that its strategic protein degradation partnership with Bristol Myers...
Neutral
●
PRNewsWire
●
4 days ago
New three-year grant from the Gates Foundation extends a 2023 project to help global health researchers predict potential fetal development risks posed by novel drug candidates Evotec's human stem cell-based platform enables better-informed decisions regarding which drug candidates to advance into clinical testing Continued collaboration underscores Evotec's capabilities in advanced human cell-...
Neutral
●
PRNewsWire
●
15 days ago
Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER) Robust commercial momentum:  Net sales* in D&PD base business increased 24% vs.
Neutral
●
PRNewsWire
●
about one month ago
Will lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of global experience in pharma, biotechnology and academia HAMBURG, Germany, Oct. 15, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Jo...
Neutral
●
PRNewsWire
●
about 2 months ago
Dr. Cord Dohrmann to step down as of September 30, 2026 Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026.
Neutral
●
PRNewsWire
●
2 months ago
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program Supports development of countermeasures against orthopoxviruses, a high-priority biological threat family that includes viruses responsible for smallpox Delivers integrated process development, regulatory submission and manufacturi...
Neutral
●
PRNewsWire
●
3 months ago
Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY® BiTco designed to boost T cell activation by engaging a costimulatory signaling pathway LOGIBODY® designed to enhance precision of T cell activation based on multispecific antigen signature HAMBURG, Germany an...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today